4.1.1 The antibody moiety of an ADC is manufactured according to well-established biomanufacturing protocols. Antibodies are commonly made in recombinant Chinese hamster ovary (CHO) cells and purified with chromatographic methods. The bulk drug substance is often released according to standard quality criteria before conjugated to the payload. More information regarding antibody and other mammalian-based biologics manufacturing and the biologics CDMO market can be found in our report Mammalian Cell Culture, Biologics: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
4.2.1 Conjugating the small molecule payload to an antibody is fundamentally a chemical process, which would optimally be performed in an organic solvent such as 20% dimethyl sulfoxide (DMSO) or 20% dimethylacetamide (DMAc).[60] The difficulty, therefore, is performing this reaction with a water-soluble antibody. If the payload is a highly potent cytotoxin, this step, therefore, must also be performed with proper isolation techniques, as will all downstream processing from this point. presents an overview of ADC manufacturing.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
4.3.1 After the chemical conjugation is performed, the organic solvents must be removed as quickly as possible to prevent aggregation. This is typically performed through tangential flow filtration (TFF). The filter membrane must be chosen carefully to ensure compatibility with the organic solvent being removed, and the molecular weight cutoff must be sufficient to remove aggregated antibodies.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
4.4.1 The basic operations of final formulation and fill/finish for an ADC are fundamentally similar to those for a naked antibody, but with the added challenge that all operations must comply with an occupational exposure limit (OEL) below 50 ng/m3.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
4.5.1 Compared to other cutting-edge therapeutics, such as gene therapies, the regulatory landscape for ADCs is relatively clear. The long history of data with both biologics and small molecules provides a solid foundation for ADC regulatory decisions. In 2011, the FDA declared that ADCs would be regulated as biologics because the biologic moiety dominates the quality characteristics. For this reason, ADCs are regulated by CBER (not CDER) and BLAs (not NMEs) for market approval.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.